RARX Ra Pharmaceuticals Inc.

21.25
+0.67  (+3%)
Previous Close 20.58
Open 20.39
Price To Book 4.33
Market Cap 896505986
Shares 42,188,517
Volume 160,329
Short Ratio
Av. Daily Volume 493,389

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met endpoints - December 10, 2018. Data to be presented at AAN May 7, 2019, 11:30 a.m. Phase 3 trial to commence 2H 2019.
RA101495 zilucoplan
Myasthenia Gravis (MG)
Phase 3 trial to be initiated 1H 2019.
RA101495
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1b PK data released September 26, 2018.
RA101495 SC
Atypical hemolytic uremic syndrome (aHUS)

Latest News

  1. Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
  2. Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study
  3. Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting
  4. Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  5. Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
  6. Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
  7. 5 Clinical-Stage Biotech Stocks to Buy
  8. Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  9. Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX)
  10. Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  11. The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
  12. Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today
  13. Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
  14. Here's Why Ra Pharmaceuticals Inc. Is Soaring Today
  15. Ra Pharma Shares Rally: What You Need To Know
  16. Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
  17. Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck
  18. Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
  19. ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  20. Ra Pharmaceuticals to Present at Upcoming Investor Conferences